Primary: The number and duration of asthma exacerbations will diminish with the regular use of a bacterial lysate. Secondary: -Regular bacterial lysate treatment improves health (pulmonary function, quality of life, medication use). - Respiratory-…
ID
Bron
Verkorte titel
Aandoening
asthma, respiratory tract infections, bacterial lysates, inflammation
Ondersteuning
Other:
- European Society for Pediatric Infectious Diseases (ESPID)
- Coolsingel foundation Rotterdam
- Vifor Pharma (requested by the PI)
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Total number of asthma exacerbations within 18 months after initiation of intervention.
Achtergrond van het onderzoek
Rationale: Bacterial lysates can modulate the immune system by effects on T-cells (skewing to the Th1-type by Treg cells) and on the inflammatory response to microorganisms. There is evidence for a reduction of infectious- and asthmatic symptoms in young children after using bacterial lysates. Yet, the effect of bacterial lysates on reduction of asthma severity and inflammatory parameters in adolescents and adults with moderate to severe asthma has not yet been studied. However, they might well benefit well from reduction of respiratory infections and attenuation of Th2-related inflammation. Therefore, we want to initiate a clinical- and laboratory study into the effects of regular treatment with bacterial lysates in adolescents and adults with proven asthma.
Main objective: To diminish the number and duration of asthma exacerbations with the regular use of a bacterial lysate.
Study design: Investigator-initiated double-blind randomized controlled trial.
Study population: Patients aged 12-60 years with proven asthma (airway responsiveness proven by reversibility and histamine PC20 < 8 mg/ml)) who have recurrent airway signs and symptoms despite optimal maintenance medication (medium/high dose inhalation corticosteroid and long-acting B2-agonist; GINA 4) and >= 2 exacerbations in the previous year.
Intervention (if applicable): Bacterial lysate OM-85 (Broncho-Vaxom, OM Pharma) 7 mg capsules versus identical placebo capsules; given in the first consecutive 10 days of each month (October-March (6 months/year)), during 2 years.
Main study parameters/endpoints: Number of astma exacerbations within 18 months after initiation of intervention.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Broncho-Vaxom is a bacterial lysate that has been used for years in children and adults with recurrent respiratory tract infections. However, for study purposes, it is hardly studied in asthmatic individuals, till now only in young children. In older subjects with COPD, bacterial lysates seem to have a positive effect on lung health. We want to investigate whether this observed positive effect on lung health could also be observed in adolescent and adult asthmatic patients.
Doel van het onderzoek
Primary:
The number and duration of asthma exacerbations will diminish with the regular use of a bacterial lysate.
Secondary:
-Regular bacterial lysate treatment improves health (pulmonary function, quality of life, medication use).
- Respiratory- and gut microbial colonization dynamics change with the regular use of a bacterial lysate
-Airway- and blood immunological markers (T-cell dynamics; cytokine production, ILC2-activity) will change with the regular use of a bacterial lysate.
Onderzoeksopzet
Primary outcome: T= 18 months.
Other outcomes: T=18 and T=30 months
Onderzoeksproduct en/of interventie
Bacterial lysate OM-85 (Broncho-Vaxom, OM Pharma) 7 mg capsules versus identical placebo capsules; given in the first consecutive 10 days of each month (October-March (6 months/year)), during 2 years.
Publiek
G.A. Tramper
Kleiweg 500
Rotterdam 3045 PM
The Netherlands
010-4617126
g.tramper@franciscus.nl
Wetenschappelijk
G.A. Tramper
Kleiweg 500
Rotterdam 3045 PM
The Netherlands
010-4617126
g.tramper@franciscus.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Subjects aged 12-60 years with proven asthma (airway responsiveness proven by reversibility or histamine PC20 < 8 mg/ml)) who have recurrent airway signs and symptoms despite optimal maintenance medication (medium/high dose inhalation corticosteroid and long-acting ¦Â2-agonist; GINA 4).
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
-Other relevant respiratory conditions, e.g. OSAS, bronchiectasis
-Systemic immunological diseases/systemic immunosuppression
-Current smoking or past smoking > 10 pack years
-Other untreated co-morbidity, such as gastro-esophageal reflux disease, ENT problems, psychological disorders
-Non-compliance to current medication or inhalation technique
-Communication difficulties
-Pregnancy or planned pregnancy within 2 years
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5752 |
NTR-old | NTR6018 |
CCMO | NL57294.101.16 |
OMON | NL-OMON43072 |